8:25 am Chairs Opening Remarks
Delving into the Current Developments to Target Intermediate AMD
8:30 am Comparing the Opportunities Available in Intermediate AMD and Geographic Atrophy
Synopsis
- Delving into the differences faced in patient recruitment for iAMD and GA
- Understanding how the perspectives of the FDA differ between iAMD and GA
- Identifying the key differences in end points for iAMD and GA
9:00 am Evaluating the Viability of Statins to Treat Dry AMD
Synopsis
- Leveraging the repurposing to target AMD at earlier stages of the disease
- Delving into the mechanism that prevents patients from developing late-stage blindness
- Assessing proof-of-concepthuman data and outlining plans for an upcoming phase 2 trial
9:30 am Leveraging Inflammation Inhibition to Target Earlier Stages of Dry AMD
Synopsis
- Assessing how to prevent the transition from the early (iAMD) ot later (GA) stage of dryA MD
- Outlining the benefits of utilizing an oral drug for the treatment of the early (iAMD) form of dryA MD
Gaining a Deeper Understanding of the Underlying Causes of Dry AMD to Inform Therapeutic Drug Development and Target Selection
10:00 am Roundtable Discussion: Exploring the Mechanisms of the Different Causes of Dry AMD
Synopsis
- As more therapeutics are progressing through company pipelines, it is more important than ever to have a clear understanding on the mechanistic causes of dry AMD
- Explore the evidence for the different mechanisms being involved in dry AMD
- Assess the current preclinical models for representing the different mechanism
- Discover the potential therapies available to target each mechanism
10:30 am Morning Break and Networking
11:00 am Understanding the Complexity of Dry-AMD: A Multifactorial Perspective
Synopsis
- Taking a holistic look the mechanisms causing dry AMD
- Discovering potential therapeutics capable of being directed towards multiple targets
- Understanding how the different mechanisms affect one another
11:30 am Exploring the Role of Long Chain (LC) & Very Long Chain (VLC) Polyunsaturated Fatty Acids (PUFA) in Vision to Better Inform Dry AMD Therapeutic Development
Synopsis
- Review of the endogenous biosynthetic pathway for LC and VLC PUFA
- Genetic and Epigenetic affects on the LC and VLC PUFA biosynthetic pathway and consequences for vision ELOVL2 retinal gene therapy
12:00 pm Utilizing Docosahexaenoic Acid (DHA) as a possible treatment for Dry AMD
Synopsis
- Exploring the evidence that DHA is oxidized in dry AMD
- Assessing the capabilities of deuterated DHA to provide protection against oxidative damage in the retina
- Evaluating available preclinical data
12:30 pm Lunch and Networking
1:30 pm Classical Complement Inhibition Preserves Visual Function with ANX007
Synopsis
- Understand importance of classical complement inhibition
- Comprehend how photoreceptor and synapse preservation protects vision
- Showcase ANX007 in Geographic Atrophy
Advancing a Combined Pluripotent Stem Cell and Device Solution for Geographic Atrophy
2:00 pm Experience in Developing a Combination Pluripotent Stem Cell/Device Product for Geographic Atrophy
Synopsis
- Approach to qualifying the cells and device
- Studies to test the safety and efficacy of the combined product
- Regulatory review
2:30 pm Afternoon Break and Networking
Investigating the Latest Advancements for Improving the Delivery of Dry AMD Therapeutics
3:00 pm Leveraging Clinical Data to Evaluate a Single Dose Intravitreal Administration of AVD-104
Synopsis
- Assessing the dose escalation and safety data
- Highlighting the benefits of using our chosen molecule
- Outlining the trial design for the 2 year trial with a 12 month primary endpoint
3:30 pm Leveraging Preclinical Data to Ensure Successful Delivery of an AAV-based Gene Therapy After Transition into the Clinic
Synopsis
- Overcoming barriers to efficient intravitreal delivery of AAV-based gene therapy to the retina
- Employing directed evolution in nonhuman primates to discover novel retinotropic AAV vectors for clinical gene therapy
- Exploring key translational research considerations to facilitate clinical trial development
4:00 pm Expanding Optogenetics Vision Restoration to GA via Laser Delivery of Multi-Characteristic Opsin
Synopsis
- Discuss potential of Optogenetics to improve visual acuity in macular degeneration patients from proof of concept data in human
- Assessing the latest preclinical data on the use of a laser delivery
- Exploring the platform for different retinal indications